All Articles
The Role of the Pharmacist after Dobbs v. Jackson Women’s Health Organization Ruling
The Hematology/Oncology Pharmacy Association (HOPA) is committed to optimizing cancer care for all individuals. The recent U.S. Supreme Court decision, which overturned Roe v. Wade, imposes a significant barrier to the oncology community’s ability to ens
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
Ghassan K. Abou-Alfa, M.D., M.B.A. abou-alg@mskcc.org, George Lau, M.D., F.R.C.P., Masatoshi Kudo, M.D., Ph.D., Stephen L. Chan, M.D., Robin Kate Kelley, M.D., Junji Furuse, M.D., Ph.D., Wattana Sukeepaisarnjaroen, M.D., +24 for the HIMALAYA Investigator
National Survey on the Effect of Oncology Drug Shortages in Clinical Practice: A Hematology Oncology Pharmacy Association Survey
Oncology drug shortages often result in disruptions in the timing of chemotherapy treatments, alterations in the dose or regimen administered, or even missed doses when alternative agents are unavailable. The purpose of this survey was to characterize the
HOPA President Brings Expertise and Unique Perspective to Hematology/Oncology Pharmacy Practice
Heidi D. Finnes, PharmD, BCOP, FHOPA became President of the Hematology/ Oncology Pharmacy Association (HOPA) on April 1, 2022 at the association’s annual conference in Boston, Massachusetts.
HOPA Calls for Appointment of Pharmacy Professionals to Federal COVID-19 Health Equity Task Force
HOPA has joined with 13 other pharmacy organizations to call on the White House to ensure pharmacy professionals are represented in the administration’s newly appointed COVID-19 Health Equity Task Force.
Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer
These findings suggest that the combination of pembrolizumab with bevacizumab and metronomic cyclophosphamide has clinical activity with a favorable toxicity profile in treatment of recurrent ovarian cancer.